STERIS (NYSE:STE) Releases Quarterly Earnings Results

STERIS (NYSE:STE) posted its earnings results on Wednesday. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.03, Briefing.com reports. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The business had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the prior year, the business earned $2.03 EPS. STERIS’s revenue for the quarter was up 7.3% compared to the same quarter last year. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Stock Performance

Shares of NYSE STE traded down $13.45 during midday trading on Thursday, hitting $214.07. 681,380 shares of the company’s stock were exchanged, compared to its average volume of 484,904. STERIS has a 12 month low of $195.47 and a 12 month high of $248.24. The company’s 50 day moving average price is $233.17 and its 200 day moving average price is $227.60. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $21.11 billion, a PE ratio of 52.93 and a beta of 0.85.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be given a $0.57 dividend. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.07%. STERIS’s payout ratio is 56.58%.

Insider Buying and Selling at STERIS

In other news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on STE. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Stephens reissued an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research report on Thursday. KeyCorp raised their target price on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. Finally, JMP Securities restated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.